SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin surges on launching generic Desoximetasone Topical Spray in US

27 Jul 2018 Evaluate

Lupin is currently trading at Rs. 816.45, up by 1.90 points or 0.23% from its previous closing of Rs. 814.55 on the BSE.

The scrip opened at Rs. 816.60 and has touched a high and low of Rs. 824.90 and Rs. 811.00 respectively. So far 143212 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1132.00 on 27-Jul-2017 and a 52 week low of Rs.723.55 on 15-May-2018.

Last one week high and low of the scrip stood at Rs. 825.95 and Rs. 793.15 respectively. The current market cap of the company is Rs. 37044.91 crore.

The promoters holding in the company stood at 47.01%, while Institutions and Non-Institutions held 37.89% and 15.10% respectively.

Lupin has launched Desoximetasone Topical Spray, 0.25%, having received an approval from the United States Food and Drug Administration (USFDA) earlier. Desoximetasone Topical Spray, 0.25% had annual sales of around $18.7 million in the US (IQVIA MAT May 2018).

Lupin's Desoximetasone Topical Spray, 0.25% is the generic equivalent of Taro Pharmaceuticals U.S.A Inc.'s Topicort Topical Spray, 0.25%. It is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2326.80 2.55 (0.11%)
20-Apr-2026 15:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.00
Dr. Reddys Lab 1226.10
Cipla 1228.55
Zydus Lifesciences 935.00
Lupin 2326.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×